Electrophysiological Biomarkers of Kynurenine Pathway Modulator AV-101 in Healthy Volunteers: Treating Suicidal Veterans

Purpose: The purpose of this study is to test the effects of drug AV-101 (4-chlorokynurenine) on brain mechanisms related with suicide risk. AV-101 is thought to influence the kynurenine pathway (a chemical pathway located in brain cells) and NMDA receptors (a chemical lock that can be opened or closed to influence brain cell activity), two brain mechanisms that could be involved in suicidal ideation, suicide attempt and suicide. AV-101 is an oral medication not yet approved for any illness. AV-101 has been tested in healthy humans, is currently being tested for treatment of depression. We will be examining the dose-response effects of AV-101 on brain functioning using neurophysiological measures (EEG) that are sensitive to changes in glutamate functioning.

Description: Baylor College of Medicine and the Michael E. DeBakey VA Medical Center are conducting a clinical trial in healthy OIF/OEF/OND veterans to investigate a drug (AV-101) for the treatment of suicide.

If eligible, participants will receive the study treatments and all study-related care at no cost. Compensation will also be provided for time and travel.

All inquiries are confidential.


Study Coordinator mood@bcm.eduPhone 1: (713) 689-9856
IRB: h-41830




Oct 24, 2018